Research & Development

Developing the leading the treatment for all forms of acute infectious conjunctivitis

We are a clinical stage ophthalmic pharmaceutical company.

We are exclusively focused on developing the leading treatment for acute infectious conjunctivitis (also known as pink eye).

Our lead product candidate, OKG-0303, is being developed to treat acute infectious conjunctivitis. It is a fixed dose eyedrop consisting of a proprietary antiviral, an ocular decongestant and an antibacterial.

Dig Deeper into our Research & Development

Acute Infectious Conjunctivitis

RUBY Trial

Latest News & Press

View All News

Press Release

Okogen, Inc., Announces Ophthalmology Industry Veteran Joshua Moriarty as New Chief Executive Officer

March 8, 2022

Press Release

Safe, Effective and Dose Responsive Anti-Viral Activity of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis–Phase 2 Interim Analysis Results from RUBY Clinical Trial

April 29, 2021

Press Release

Okogen Initiates Phase 2 Clinical Trial (RUBY) of OKG-0301 in Patients

January 31, 2019